Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia

Abstract

Xavier Thomas Hospices Civils de Lyon, Hematology, Lyon-Sud Hospital, Pavillon Marcel Bérard, France Abstract: Monoclonal antibodies are likely to make a considerable contribution in the treatment of acute lymphoblastic leukemia (ALL). High expression of CD22 antigen is found on the surface of leukemia cells in ALL. Inotuzumab ozogamicin, a CD22 monoclonal antibody conjugated to calicheamicin, which has shown efficacy in patients with lymphomas, has also shown encouraging activity in relapsed or refractory ALL with a high morphologic and molecular response rate. This article summarizes the current approaches to treating ALL with inotuzumab ozogamicin, based on available data from the literature. Keywords: monoclonal antibody, inotuzumab ozogamicin, CMC-544, acute lymphoblastic leukemia, targeted therapy